Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DanBiotech is a South Korean biotechnology company focused on the discovery and development of innovative therapeutic antibodies and recombinant proteins for oncology and inflammatory diseases. The company leverages its proprietary platform for high-affinity antibody selection and protein engineering to target immune checkpoints and pro-inflammatory cytokines. Their pipeline includes several pre-clinical candidates targeting PD-1/PD-L1 and VISTA for cancer immunotherapy, as well as treatments for autoimmune conditions like atopic dermatitis and rheumatoid arthritis. DanBiotech also provides specialized R&D services, including protein production and cell line development, to academic and industrial partners.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DAN Biotech.